Gandara DR, Von Pawel J, Sullivan RN, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001).
Commissie voor Beentumoren nog steeds onmisbaar
apr 2022 | Bot en wekedelentumoren, Orthopedie